1.44
price down icon5.26%   -0.08
after-market Handel nachbörslich: 1.45 0.01 +0.69%
loading

Biovie Inc Aktie (BIVI) Neueste Nachrichten

pulisher
03:30 AM

Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news

03:30 AM
pulisher
01:40 AM

BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news

01:40 AM
pulisher
09:12 AM

BioVie completes enrollment in Phase 2 Long COVID trial - Proactive financial news

09:12 AM
pulisher
09:05 AM

BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus

09:05 AM
pulisher
08:41 AM

BioVie completes enrollment in Long COVID treatment trial By Investing.com - Investing.com Canada

08:41 AM
pulisher
08:00 AM

Long COVID patients await results as BioVie trial hits full enrollment - Stock Titan

08:00 AM
pulisher
May 25, 2026

BioVie Inc. (BIVI) Gains 2.7% as Shares Test Near-Term ResistanceCTA Positioning - Newser

May 25, 2026
pulisher
May 22, 2026

BioVie Inc. (BIVI) Q1 2026 Earnings: Narrowing Losses and Clinical Progress Buoy Investor SentimentStrong Earnings Momentum - Newser

May 22, 2026
pulisher
May 22, 2026

BioVie Inc.Common stock (NQ: BIVI - The Chronicle-Journal

May 22, 2026
pulisher
May 20, 2026

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3 - Bez Kabli

May 20, 2026
pulisher
May 20, 2026

BioVie (BIVI) Rallies +1.53% as Bulls Target $1.40 2026-05-20McClellan Summation - Newser

May 20, 2026
pulisher
May 19, 2026

BioVie completes final patient visit in Parkinson's drug trial - Proactive financial news

May 19, 2026
pulisher
May 18, 2026

BioVie (BIVI) Completes Patient Evaluations for Parkinson's Tria - GuruFocus

May 18, 2026
pulisher
May 18, 2026

BioVie completes patient visits in Parkinson’s disease trial By Investing.com - Investing.com Nigeria

May 18, 2026
pulisher
May 18, 2026

BioVie completes patient visits in Parkinson’s disease trial - Investing.com

May 18, 2026
pulisher
May 18, 2026

BioVie Inc. Completes Final Patient Visit in SUNRISE-PD Phase 2 Trial for Bezisterim in Early-Stage Parkinson's Disease - Quiver Quantitative

May 18, 2026
pulisher
May 18, 2026

Experimental Parkinson’s drug bezisterim finishes key trial, results due Q3 - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Why BioVie (BIVI) Just Surged +3.82% — Key Levels Ahead 2026-05-18Most Discussed Stocks - Newser

May 18, 2026
pulisher
May 12, 2026

TradingKey - TradingKey

May 12, 2026
pulisher
May 11, 2026

BioVie | 10-Q: Quarterly report - Moomoo

May 11, 2026
pulisher
May 11, 2026

BIOVIE ($BIVI) Releases Q3 2026 Earnings - Quiver Quantitative

May 11, 2026
pulisher
May 11, 2026

BioVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com

May 11, 2026
pulisher
May 11, 2026

[10-Q] BIOVIE INC. Quarterly Earnings Report - Stock Titan

May 11, 2026
pulisher
May 09, 2026

BioVie nears data readout for potential first treatment targeting long COVID symptoms. - Pluang

May 09, 2026
pulisher
May 09, 2026

BioVie CEO shares insights into long COVID trialICYMI - Proactive financial news

May 09, 2026
pulisher
May 08, 2026

Why BioVie (BIVIW) leadership matters more than you think (Smart Money Outflows) 2026-05-08Analyst Recommended Stocks - newser.com

May 08, 2026
pulisher
May 08, 2026

BioVie (BIVIW) quarterly earnings show no revenue or profit data, raising transparency concerns among market participants.Free Signal Network - Newser

May 08, 2026
pulisher
May 07, 2026

Alumni StoriesCuong Do - Dartmouth Tuck School of Business

May 07, 2026
pulisher
May 04, 2026

BioVie advances long COVID trial, top-line data expected by summer - Proactive financial news

May 04, 2026
pulisher
May 01, 2026

12 Health Care Stocks Moving In Friday's After-Market SessionAkanda (NASDAQ:AKAN), BioVie (NASDAQ:BIVI - Benzinga

May 01, 2026
pulisher
May 01, 2026

BioVie Investor Deadline Approaching - TMX Newsfile

May 01, 2026
pulisher
Apr 29, 2026

What influences BioVie (BIVIW) stock price action |Crowd Sentiment Stocks - Newser

Apr 29, 2026
pulisher
Apr 28, 2026

BioVie Shareholder Notice - TMX Newsfile

Apr 28, 2026
pulisher
Apr 28, 2026

BIVIW Price History for Biovie WT Stock - Barchart.com

Apr 28, 2026
pulisher
Apr 27, 2026

BioVie to host KOL event highlighting Bezisterim's potential in Parkinson's Disease - Proactive financial news

Apr 27, 2026
pulisher
Apr 27, 2026

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 - ChartMill

Apr 27, 2026
pulisher
Apr 24, 2026

Why United Rentals Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Sahm

Apr 24, 2026
pulisher
Apr 24, 2026

BioVie stock dips on pricing $12M securities offering - MSN

Apr 24, 2026
pulisher
Apr 22, 2026

BioVie (BIVI) Market Position | Q3 2025: Better Than ExpectedCommunity Driven Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026
pulisher
Apr 22, 2026

Is BioVie (BIVI) stock showing bullish signals today | BioVie Inc. Delivers 13.5 Percent EPS Beat Topping Analyst EstimatesTrending Entry Points - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026
pulisher
Apr 22, 2026

BIVIW (BioVie) PS Ratio : (As of Apr. 27, 2026) - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

BIVIW (BioVie) Cyclically Adjusted PB Ratio : (As of Apr. 22, 2026) - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

BIVIW (BioVie) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2026) - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

BIVIW (BioVie) EV-to-EBIT : 0.00 (As of Apr. 22, 2026) - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

BioVie Inc (BIVIW) Valuation - GuruFocus

Apr 22, 2026
pulisher
Apr 21, 2026

BioVie Inc (BIVIW) Competitors 2026 - GuruFocus

Apr 21, 2026
pulisher
Apr 21, 2026

BioVie Inc (BIVIW) Stock HoldersInstitutional & Insider Ownership - GuruFocus

Apr 21, 2026
pulisher
Apr 21, 2026

BIVIW (BioVie) Net Income From Continuing Operations : $-17.43 Mil (TTM As of Dec. 2025) - GuruFocus

Apr 21, 2026
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
Kapitalisierung:     |  Volumen (24h):